Hon. Maria Elvira Salazar, a member of the U.S. House of Representatives, has disclosed the sale of Moderna, Inc. (MRNA) common stock in a Periodic Transaction Report filed under the STOCK Act. The transaction, executed by the member personally through a UBS Brokerage Account, took place on August 19, 2026, and falls within the $1,001 to $15,000 disclosure range required by law.
The filing is one of thousands submitted annually by lawmakers, who are required to report trades within 45 days regardless of size. This particular disclosure has been classified by our tracking system simply as a congress sale, meaning no purchase or additional context accompanies the transaction in the public record.
A Notable Timing Overlap
What makes this filing worth watching is its proximity to another sale of the same stock. Company insider Mock James M, associated with Moderna, also sold shares of MRNA on August 27, 2026, according to separate insider trading disclosures. That transaction was recorded with a $0 value figure, and it occurred within roughly a week of Rep. Salazar’s reported sale date, placing both transactions within the same 30-day window.
Such overlaps between congressional trading disclosures and corporate insider filings are not uncommon, and they do not by themselves indicate coordination or any improper conduct. Members of Congress and corporate insiders operate under entirely separate disclosure regimes, and STOCK Act filings exist precisely so that the public can observe when lawmakers hold or trade individual securities. The requirement to disclose is not an accusation; it is a transparency mechanism built into federal ethics law.
Still, when a member of Congress and a company insider both reduce their position in the same stock within a short span of time, it becomes a data point worth logging for readers who track these patterns across sectors. Moderna has remained a frequently watched name in congressional trading data given its visibility in public health policy discussions, making any disclosed activity in MRNA shares of interest to observers who follow the intersection of policy and portfolio decisions.
Readers who follow broader institutional positioning may also want to see how large asset managers are adjusting their own holdings each quarter. Our ongoing coverage of Renaissance Technologies LLC: 13F Portfolio Moves Tracked Quarterly offers a comparison point for how institutional and individual trading signals can diverge or align over time.
No further transactions tied to this specific filing have been reported as of this writing, and the disclosure stands as a routine, legally required report of a sale that occurred within the specified date and dollar range.